The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for malignant pleural mesothelioma (MPM).
From the blog
Quality of Life After Pleurectomy/Decortication vs. Extra Pleural Pneumonectomy
On the rare instance that mesothelioma is diagnosed in the early stages of the disease, patients have the option for surgery. There are several surgical procedures used to treat mesothelioma. Some mesothelioma surgeries aim to provide a curative effect, while others are performed for palliative purposes. Pleurectomy/decortication (P/D) and extra[…]
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in patients with advanced or metastatic solid tumors.
Phase 1 Clinical Trial For Those With Peritoneal Mesothelioma Underway
Mesothelioma is a rare cancer affecting only about 3,000 Americans each year. Most of those diagnosed are diagnosed with pleural mesothelioma, but a small number (approx. 500 per year) are diagnosed with peritoneal mesothelioma, which is mesothelioma in the abdominal lining. With so few diagnosed with peritoneal mesothelioma, studying and[…]
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
This is a first-in-human, open-label, non-randomized, two-part phase 1 trial of INBRX-109, which is a recombinant humanized multivalent antibody targeting the human death receptor 5 (DR5).
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma (INFINITE)
Primary Outcome Measures Overall Survival [ Time Frame: 60 months ] Time to death (from any cause) from randomization Secondary Outcome Measures Survival rate [ Time Frame: 60 months ] Number of deaths (from any cause) from randomization Progression Free Survival [ Time Frame: 60 months ] Time from randomization[…]
Decade Long Study Reveals Potential for Early Detection in Mesothelioma
For many patients who are suffering from malignant mesothelioma, their diagnosis came quickly after experiencing symptoms. In many cases, this is because symptoms of mesothelioma typically do not appear until the cancer has fully developed and it’s in the later stages. For those suffering from pleural mesothelioma – the most[…]
Researchers Theorize Drug from the 1800s Could Improve Radiation Treatments in Mesothelioma Patients
Radiation therapy for those suffering from mesothelioma is not typically the first line of treatment because of its overall effectiveness. High-energy x-rays, gamma rays, and neutrons that make up radiation treatment aim to shrink tumors and ultimately kill cancer cells, but since mesothelioma tumors often have an irregular shape, it[…]
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.
Phase III Clinical Trial for Nintedanib Discontinued After Yielding Negative Results
Disappointing results from the LUME-Phase III clinical trial regarding nintedanib is a setback for scientists and researchers who were hopeful they were on the brink of finding a new, first line treatment for those suffering from mesothelioma. Results from the Phase II clinical trial – published earlier this year –[…]
